Other randomized controlled trials were terminated prematurely due to recruitment difficulties. Furthermore, case-control studies provided nonrandomized comparative data evaluating the impact of aggressive treatment on survival for patients with colorectal PM comparing outcomes with CRS+HIPEC vs systemic chemotherapy alone. The current practice and evidence for this combined modality is mainly based on large retrospective cohort studies and some multicentric prospective or retrospective studies. These analyses reported median overall survival rates up to 6 months and a 5-year overall survival up to 40% in highly selected patients successfully treated withCRS and HIPEC, even with curative intent